Top Page
Medibank Private
(Sydney:MPL)
Medibank Private (MPL) vs. iShares MSCI Australia ETF (EWA)
Medibank Private Business Overview & Revenue Model
Medibank Private Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.56B | 8.56B | 8.02B | 7.40B | 7.09B | 6.98B |
| Gross Profit | 8.56B | 8.56B | 8.02B | 7.40B | 7.10B | 7.03B |
| EBITDA | 746.80M | 750.80M | 806.50M | 520.60M | 635.10M | 715.00M |
| Net Income | 500.80M | 500.80M | 492.50M | 511.10M | 393.90M | 441.20M |
Balance Sheet | ||||||
| Total Assets | 4.70B | 4.70B | 4.69B | 4.39B | 4.55B | 3.92B |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 927.90M | 695.10M | 831.30M | 671.70M |
| Total Debt | 209.00M | 209.00M | 218.30M | 55.30M | 76.90M | 93.40M |
| Total Liabilities | 2.36B | 2.36B | 2.38B | 2.30B | 2.61B | 2.02B |
| Stockholders Equity | 2.34B | 2.34B | 2.31B | 2.08B | 1.95B | 1.91B |
Cash Flow | ||||||
| Free Cash Flow | 369.70M | 369.70M | 810.90M | 216.30M | 927.60M | 463.10M |
| Operating Cash Flow | 380.90M | 380.90M | 868.50M | 258.20M | 962.70M | 498.20M |
| Investing Cash Flow | -22.70M | 110.50M | -110.80M | -15.20M | -637.80M | -322.10M |
| Financing Cash Flow | -533.80M | -533.80M | -487.30M | -419.10M | -399.90M | -375.80M |
Medibank Private Technical Analysis
Medibank Private Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$3.28B | 16.45 | 18.51% | 4.17% | 5.90% | 7.22% | |
71 Outperform | AU$13.08B | 26.13 | 21.28% | 3.73% | 6.37% | 1.73% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
66 Neutral | AU$29.84B | 9.93 | 18.97% | 4.68% | 5.93% | 14.80% | |
65 Neutral | AU$18.50B | 12.31 | 12.51% | 26.88% | -0.54% | 26.37% | |
63 Neutral | AU$18.28B | 13.38 | 19.09% | 3.91% | 8.47% | 54.09% | |
60 Neutral | AU$3.63B | 19.99 | 11.17% | 2.95% | 10.98% | 23.05% |
Medibank Private Corporate Events
Medibank has announced the retirement of The Hon Jay Weatherill AO as a non-executive director, effective 31 December 2025, and has lodged a Final Director’s Interest Notice with the ASX in accordance with listing requirements. The filing confirms that Weatherill held no Medibank securities in his own name at the time of ceasing to be a director, indicating no direct equity stake remains tied to his tenure and signalling a clean governance transition for the board and its stakeholders.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.50 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has notified the ASX of the cessation of 152,254 performance rights (security code MPLAA) as of 31 December 2025, after the conditional rights lapsed because their vesting conditions were not met or became incapable of being satisfied. The lapse of these performance rights effectively reduces the pool of potential future equity issuance under this particular incentive arrangement, which may marginally impact dilution expectations for existing shareholders but does not alter the company’s current issued capital structure.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.50 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank has announced a change in the recording of director David Koczkar’s interests in company securities, clarifying that while the entities through which his holdings are held have changed, the total number of Medibank securities in which he has a direct and indirect interest remains unchanged from the disclosure lodged on 19 December 2025. The update is a technical adjustment to the register of interests rather than a change in Koczkar’s overall economic exposure to Medibank, and reflects the company’s ongoing compliance with ASX disclosure requirements and corporate governance obligations, with no direct operational or strategic impact indicated for shareholders or other stakeholders.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has notified the market of the issue of 3,230,852 unquoted performance rights under its employee incentive scheme. These performance rights, which are not intended to be quoted on the ASX, were issued on 12 December 2025 and reflect the company’s ongoing use of equity-based incentives to align employee remuneration with long-term shareholder value.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced key dates for the first half of the fiscal year 2026, including the release of its half-year results on February 19, 2026. The company will host a teleconference and webcast briefing for investors and analysts on the same day, led by CEO David Koczkar and CFO Mark Rogers. Additionally, Medibank has scheduled its interim dividend payment dates, with the ex-dividend date set for February 26, 2026, and the payment date on March 18, 2026. These announcements are crucial for stakeholders as they provide insights into the company’s financial performance and shareholder returns.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.05 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced the appointment of Jacqueline Hey and Dr. Lisa McIntyre as non-executive directors, effective from November 19, 2025. This strategic addition to the board is expected to enhance the company’s governance and potentially strengthen its market position, reflecting Medibank’s commitment to robust leadership and strategic oversight.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.84 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited successfully held its 2025 Annual General Meeting, where all resolutions from 2 to 7 were passed as ordinary resolutions by poll. The re-election of directors Kathryn Fagg AC and Peter Everingham, along with the election of Dr. Lisa McIntyre and Jacqueline Hey, were approved, reflecting strong shareholder support. Additionally, the adoption of the remuneration report and the grant of performance rights to the CEO were also sanctioned, indicating confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (AU:MPL) stock is a Buy with a A$5.84 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced the retirement of non-executive director The Hon Jay Weatherill AO from its board, effective 31 December 2025. Weatherill’s departure follows his recent appointment as the Australian High Commissioner to the United Kingdom. His tenure on the board, which began in March 2024, included roles on the Audit Committee and Risk Management Committee. Medibank’s Chair, Mike Wilkins, expressed gratitude for Weatherill’s contributions, particularly his expertise in public policy and reform, which significantly impacted the board’s work.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.35 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank has announced the acquisition of Better Medical, a network of 61 GP and medical clinics, for approximately $159 million. This strategic move is part of Medibank’s broader effort to enhance primary care services and support preventive health measures, addressing the growing need for investment in the healthcare system. The acquisition aligns with Medibank’s strategy to expand its health segment and is expected to contribute to its financial goals, with Better Medical anticipated to deliver significant EBITDA by mid-2026.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.35 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.
Medibank Private Limited has announced its long-term ambitions to accelerate growth as a health company, aiming to significantly increase earnings in its health segment and expand its policyholder market share by FY30. The company is focusing on four key health segments—wellbeing, primary care, community and acute care, and health insurance—to deliver greater value and drive long-term growth. CEO David Koczkar highlighted the need for a shift in the healthcare system towards prevention, community-based care, and digital health solutions, emphasizing Medibank’s role in this transition and its commitment to investing in technology and partnerships to meet evolving community needs.
The most recent analyst rating on (AU:MPL) stock is a Hold with a A$5.25 price target. To see the full list of analyst forecasts on Medibank Private stock, see the AU:MPL Stock Forecast page.